LYSOGENE news, videos and press releases - Page 3
For more news please use our advanced search feature.
LYSOGENE - More news...
LYSOGENE - More news...
- Lysogene Reports its Cash Position as of 30 September 2020
- Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
- Lysogene Reports First Half 2020 Financial Results and Provides Operational Update
- Lysogene: First Half 2020 Business Update
- Lysogene Announces a Research Collaboration With the Weizmann Institute of Science
- LYSOGENE Releases the Results From June 26, 2020 Ordinary Annual and Extraordinary General Meeting
- Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
- NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product
- Lysogene: Annual Ordinary and Extraordinary General Meeting of 26 June 2020
- Lysogene Announces Presentations at Upcoming Meetings
- Kepler Cheuvreux Initiates Coverage of Lysogene
- Lysogene Announces Filing of 2019 Universal Registration Document
- Lysogene Reports Its Cash Position as of 31 March 2020
- Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update
- Lysogene Announces the Date of Its 2020 General Shareholders’ Meeting and Amends Its Financial Calendar
- Lysogene Completes €7.7 Million Capital Increase in a Placement Led by Leading Healthcare Investor OrbiMed and Lysogene Shareholder and Partner Sarepta
- Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA
- Lysogene Reports its Cash Position as of 31 December 2019
- Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases
- Lysogene Announces Its Corporate Agenda For 2020
- Annual Report of the Liquidity Contract Signed by Lysogene with Gilbert Dupont
- Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302
- Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer
- Lysogene Reports First Half 2019 Financial Results and Provides Operational Update
- Lysogene Announces the Appointment of Carole Deffez as New Independent Board Director
- Lysogene: A Pivotal Year 2019 for Lysogene’s MPS IIIA Phase 2-3 Clinical Trial
- Lysogene Announces Upcoming Presentations at the 2018 International MPS symposium
- Lysogene Reports Second Quarter Cash Position and Provides Business and Strategic Update
- Lysogene Announces the Nomination of Dr. Ralph Laufer as Chief Scientific Officer and Member of the Executive Team
- Lysogene Signs Partnership Agreement with Dr. Hervé Moine, Researcher at the IGBMC(1) and the SATT(2) Conectus Alsace, in the Fragile X Syndrome
